TMPRSS2 inhibitors bromhexine (OTC-Europe) and camostat (generic-Japan) may slow SARS-CoV2 entry into ACE2 cells, inhibiting viral replication safely. (https://www.drugtargetreview.com/article/61657/tmprss2-inhibitors-bromhexine-aprotinin-camostat-and-nafamostat-as-potential-treatments-for-covid-19/).

Are these potential prophylaxis agents receiving competent testing as prophylactic candidates, absent agent patentability?

More Brian Cady's questions See All
Similar questions and discussions